Panels and Topics:

Basic and Translational Science (Morning): Present the latest evidence on psilocybin, ketamine, and ibogaine, grounding the Forum in rigorous science and clinical practice.

Manufacturing and Supply (Late Morning): Explore how GMP manufacturing and pharmaceutical standards underpin safe, scalable psychedelic therapies.

Educational Demonstration (Late Morning): A theatrical portrayal of the patient journey through psychedelic therapy, making the science tangible for policymakers.

Legal Frameworks (Midday): Examine lessons from Oregon, Colorado, and New Jersey on how to regulate psychedelic and cannabis access.

Clinical Models (Early Afternoon): Share experiences of ibogaine and psychedelic care delivery across different systems and countries.

Public Sector Roadmaps (Afternoon): Map strategies for responsibly integrating psychedelics and cannabis into municipal and state health systems.

Economics and Data (Afternoon): Highlight financial models, reimbursement structures, and usage data that support policy and coverage decisions.

Patient Panel (Late Afternoon): Lived experiences of treatment highlight both promise and ongoing barriers to access.

Keynote Interview (5:00 PM): Bryan Hubbard outlines the roadmap behind Texas’s $50M ibogaine rollout, offering a model for scalable adoption.